(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 January 2013 (03.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/003625 A2

(51) **International Patent Classification**:
C07K 16/28 (2006.01)

(21) **International Application Number**:
PCT/US2012/044703

(22) **International Filing Date**:
28 June 2012 (28.06.2012)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/502,167 28 June 2011 (28.06.2011) US
PCT/US2012/044451 27 June 2012 (27.06.2012) US

(71) **Applicant** *(for all designated States except US)*: **OXFORD BIOTHERAPEUTICS LTD.** [GB/GB]; 94a Milton Park, Arbingdon, Oxon OX14 4RY (GB).

(72) **Inventors; and**
(75) **Inventors/Applicants** *(for US only)*: **ROHLFF, Christian** [DE/GB]; Oxford Bio Therapeutics Ltd., 94a Milton Park, Abington, Oxon OX14 4RY (GB). **TERRETT, Jonathan, Alexander** [GB/US]; 5941 Optical Court, San Jose, CA 95138 (US).

(74) **Agents**: **SILVA, Robin, M.** et al.; Morgan Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

WO 2013/003625 A2

(54) **Title**: ANTIBODIES

(57) **Abstract**: The invention provides antibodies which bind to the ADP-ribosyl cyclase 2. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of human cancers, including acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer and pancreatic cancer and human inflammatory diseases, including asthma, gout, crohns, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, diabetes and atherosclerotic.